<DOC>
	<DOCNO>NCT02183870</DOCNO>
	<brief_summary>EUCROSS phase II trial evaluate efficacy safety crizotinib patient adenocarcinoma lung harbour ROS1 translocation . Patients treat 250mg crizotinib bid progression intolerable toxicity .</brief_summary>
	<brief_title>EUCROSS : European Trial Crizotinib ROS1 Translocated Lung Cancer</brief_title>
	<detailed_description>EUCROSS phase II trial evaluate efficacy safety crizotinib patient adenocarcinoma lung harbour ROS1 translocation . In individual treatment attempt ongoing phase I trial crizotinib show remarkable effect select subgroup lung cancer patient . Crizotinib tyrosine kinase inhibitor , block catalytic activity rearrange ALK ROS1 well MET . The patient eligible trial treat 250mg crizotinib twice-daily . Tumor response treatment assess every 6 week CT MRI scan . In case progression treatment beyond may conduct clinically indicate . To identify mechanism resistance crizotinib treatment , optional re-biopsy may perform case fresh frozen tumor material analyze University Cologne .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Patients adenocarcinoma lung locally advance metastatic independent number prior line therapy , i.e . include nonpretreated patient ( UICC stage IIIB IV ) Positive ROS1 translocation central FISHtesting Ability swallow pill Age &gt; 18 year ECOG performance status 0 2 Life expectancy least 12 week Disease measurable per Response Evaluation Criteria Solid Tumors ( RECIST , version 1.1 ) Any prior treatment ( chemotherapy , radiation surgery ) must complete least 2 week prior initiation study medication Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 14 day prior screen : Hemoglobin ≥ 8.0 g/dL Absolute neutrophil count ( ANC ) ≥ 1,000 /mm3 Platelet count ≥ 50 000/µL Total bilirubin ≤ 2 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) alkaline phosphatase ( AP ) ≤ 2,5 x ULN ≤ 5 x ULN case liver involvement PTINR/PTT ≤ 1.5 x ULN Serum creatinine ≤ 2 time ULN Calculated creatinine clearance ( CLcr ) ≥ 40 ml/min ( CockcroftGault formula ) Written informed consent Negative serum pregnancy test within 3 day prior start dose premenopausal woman . Women nonchildbearing potential may include without serum pregnancy test either surgically sterile postmenopausal ≥ 1 year . Fertile men woman must effective method contraception treatment least 3 month completion treatment direct physician . Effective method contraception result low failure rate ( i.e . le 1 % per year ) use consistently correctly ( example implant , injectables , combine oral contraception intrauterine device ) . At discretion investigator , acceptable method contraception may include total abstinence lifestyle patient ensures compliance ( Periodic abstinence withdrawal acceptable method contraception ) . Previous treatment specific ALK ROS1 inhibitor Current treatment within another therapeutic clinical trial Other history ongoing malignancy would potentially interfere interpretation efficacy ( early stage chronic disease allow require active therapy intervention control ) Pregnancy breastfeed Use drug food know potent CYP3A4 inhibitor , include limited atazanavir , clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , troleandomycin , voriconazole grapefruit grapefruit juice Use drug know potent CYP3A4 inducer , include limited carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , St. John 's wort Use drug CYP3A4 substrates narrow therapeutic index , include limited dihydroergotamine , ergotamine , pimozide , astemizole , cisapride , terfenadine Active CNS metastasis . Patients brain metastasis eligible asymptomatic ≥ 14 day start study medication corticosteroid . History know carcinomatous meningitis leptomeningeal disease Known diagnosis HIV , active hepatitis B and/or C ( test mandatory ) Any person institution assignment respective authority his/her Any medical , mental psychological condition opinion investigator would permit patient complete study understand patient information Ongoing cardiac dysrhythmias CTCAE grade ≥2 , uncontrolled atrial fibrillation grade QTcF interval &gt; 470ms Patients know interstitial fibrosis interstitial lung disease Any follow within 3 month prior first crizotinib administration : Myocardial infarction , severe/unstable angina , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>NSCLC</keyword>
	<keyword>ROS1</keyword>
	<keyword>ROS1 translocation</keyword>
	<keyword>crizotinib</keyword>
	<keyword>phase II</keyword>
</DOC>